Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)

Running, not enrolling

Conditions studied: NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer

In brief

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.

Key facts

Study ID

NCT05478538

Run by

Elephas

People needed

200

Starts

2023-01-31

Expected to finish

2026-12-01

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA Medical Center — Los Angeles, California, United States
• James M Stockman Cancer Institute — Frederick, Maryland, United States
• New York Cancer & Blood Specialists — Shirley, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Gabrail Cancer Center — Canton, Ohio, United States
• JPS Health Network — Fort Worth, Texas, United States
• Baylor Scott & White Research Institute — Temple, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.